Effect of tibolone on the survival of early stage cervical adenocarcinoma patients.
10.5468/ogs.2018.61.5.584
- Author:
Seung Ho LEE
1
;
Yoon Jin CHO
;
Kyung Joo CHO
;
Mee Hyang KO
;
Sun Young JUNG
;
Seung Joo CHON
;
So Yi LIM
;
Kwang Beom LEE
Author Information
1. Department of Obstetrics and Gynecology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. leekwbm@naver.com
- Publication Type:Original Article
- Keywords:
Uterine cervical neoplasm;
Adenocarcinoma;
Tibolone;
Prognosis;
Survival
- MeSH:
Adenocarcinoma*;
Disease-Free Survival;
Gynecology;
Humans;
Medical Records;
Obstetrics;
Prognosis;
Quality of Life;
Uterine Cervical Neoplasms
- From:Obstetrics & Gynecology Science
2018;61(5):584-589
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Gynecologic oncologists are uncertain about the safety of tibolone application in cervical adenocarcinoma (AC) patients. This study examined the possible adverse effects of tibolone on the survival of cervical AC patients. METHODS: Medical records of 70 cervical AC patients with International Federation of Gynecology and Obstetrics stages IA to IB were reviewed. A bilateral salpingo-oophorectomy was performed in all patients, and survival outcomes between tibolone users (n=38) and non-users (n=32) were compared. RESULTS: A comparison of the tibolone users with non-users revealed similar clinicopathological variables. Progression-free survival (P=0.34) and overall survival (P=0.22) were similar in the users and non-users. The risks of progression (hazard ratio [HR], 1.71; 95% confidence interval [CI], 0.46–6.37; P=0.43) and death (HR, 1.59; 95% CI, 0.06–45.66; P=0.79) were also similar in both groups. CONCLUSION: Tibolone has no adverse effect on the survival of cervical AC patients and can be administered safely to this population. These findings may be helpful in improving the quality of life of cervical AC patients.
